Under construction – not a live service
Sign in
Not yet taking people in United StatesPhase 3

A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

Key facts

Where
Ann Arbor, Augusta, Birmingham, Boston, Brandon, Charleston, Cincinnati, Cleveland, Colchester, Cypress, Dallas, Denver, DuBois, El Paso, Falls Church, Galveston, Hawthorne, Houston, Huntersville, Jacksonville, Kansas City, Madison, McKinney, Murray, Naples, New Hyde Park, New York, Newport Beach, Omaha, Philadelphia, Pinehurst, Redding, Richmond, Rochester, Rock Hill, Sacramento, Saint Paul, San Antonio, San Francisco, Seattle, Spokane, St Louis, Tampa, Tucson, Tyler, and Weston, United StatesSee the 51 sites
Phase
Phase 3

Where in United States

  • University of MichiganAnn Arbor, United StatesContact: Boehringer IngelheimNo longer taking part
  • Augusta UniversityAugusta, United StatesContact: Boehringer IngelheimNo longer taking part
  • University of Alabama at BirminghamBirmingham, United StatesContact: Boehringer IngelheimNo longer taking part
  • Massachusetts General HospitalBoston, United StatesContact: Boehringer IngelheimNo longer taking part
  • Meris Clinical Research-Brandon-69466Brandon, United StatesContact: Boehringer IngelheimNo longer taking part
  • Medical University of South CarolinaCharleston, United StatesContact: Boehringer IngelheimNo longer taking part
  • University of CincinnatiCincinnati, United StatesContact: Boehringer IngelheimNo longer taking part
  • University Hospitals Cleveland Medical Center*Cleveland, United StatesContact: Boehringer IngelheimNo longer taking part
  • University of VermontColchester, United StatesContact: Boehringer IngelheimNo longer taking part
  • Horizon Clinical Research GroupCypress, United StatesContact: Boehringer IngelheimNo longer taking part
  • Baylor University Medical CenterDallas, United StatesContact: Boehringer IngelheimNo longer taking part
  • University of Texas Southwestern Medical CenterDallas, United StatesContact: Boehringer IngelheimNo longer taking part
  • National Jewish HealthDenver, United StatesContact: Boehringer IngelheimNo longer taking part
  • Clinical Research Associates of Central PADuBois, United StatesContact: Boehringer IngelheimNo longer taking part
  • El Paso Pulmonary AssociationEl Paso, United StatesContact: Boehringer IngelheimNo longer taking part
  • Inova Fairfax Medical CampusFalls Church, United StatesContact: Boehringer IngelheimNo longer taking part
  • University Of Texas Medical Branch At GalvestonGalveston, United StatesContact: Boehringer IngelheimNo longer taking part
  • New York Medical College - HawthorneHawthorne, United StatesContact: Boehringer IngelheimNo longer taking part
  • Baylor College of MedicineHouston, United StatesContact: Boehringer IngelheimNo longer taking part
  • Stern Research Partners, LLCHuntersville, United StatesContact: Boehringer IngelheimNo longer taking part
  • Mayo Clinic FloridaJacksonville, United StatesContact: Boehringer IngelheimNo longer taking part
  • University of Florida - College of MedicineJacksonville, United StatesContact: Boehringer IngelheimNo longer taking part
  • University of Kansas Medical CenterKansas City, United StatesContact: Boehringer IngelheimNo longer taking part
  • University of WisconsinMadison, United StatesContact: Boehringer IngelheimNo longer taking part
  • Metroplex Pulmonary & Sleep CenterMcKinney, United StatesContact: Boehringer IngelheimNo longer taking part
  • Intermountain HealthcareMurray, United StatesContact: Boehringer IngelheimNo longer taking part
  • Essence MD ResearchNaples, United StatesContact: Boehringer IngelheimNo longer taking part
  • Northwell HealthNew Hyde Park, United StatesContact: Boehringer IngelheimNo longer taking part
  • Icahn School of Medicine at Mount SinaiNew York, United StatesContact: Boehringer IngelheimNo longer taking part
  • New York Presbyterian Hospital/Columbia UniversityNew York, United StatesContact: Boehringer IngelheimNo longer taking part
  • New York University Langone Medical CenterNew York, United StatesContact: Boehringer IngelheimNo longer taking part
  • Newport Native Md, Inc.Newport Beach, United StatesContact: Boehringer IngelheimNo longer taking part
  • University of Nebraska Medical CenterOmaha, United StatesContact: Boehringer IngelheimNo longer taking part
  • Jefferson Health Honickman CenterPhiladelphia, United StatesContact: Boehringer IngelheimNo longer taking part
  • University of PennsylvaniaPhiladelphia, United StatesContact: Boehringer IngelheimNo longer taking part
  • Pinehurst Medical Clinic, Inc. - EastPinehurst, United StatesContact: Boehringer IngelheimNo longer taking part
  • Paradigm Clinical Research - ReddingRedding, United StatesContact: Boehringer IngelheimNo longer taking part
  • Virginia Commonwealth University Health SystemsRichmond, United StatesContact: Boehringer IngelheimNo longer taking part
  • Mayo Clinic - RochesterRochester, United StatesContact: Boehringer IngelheimNo longer taking part
  • Clinical Research of Rock HillRock Hill, United StatesContact: Boehringer IngelheimNo longer taking part
  • University of California - DavisSacramento, United StatesContact: Boehringer IngelheimNo longer taking part
  • HealthPartners Specialty Center 401 BuildingSaint Paul, United StatesContact: Boehringer IngelheimNo longer taking part
  • IMA Clinical Research San AntonioSan Antonio, United StatesContact: Boehringer IngelheimNo longer taking part
  • University of California San FranciscoSan Francisco, United StatesContact: Boehringer IngelheimNo longer taking part
  • University of WashingtonSeattle, United StatesContact: Boehringer IngelheimNo longer taking part
  • Providence Medical Research CenterSpokane, United StatesContact: Boehringer IngelheimNo longer taking part
  • Washington University School of MedicineSt Louis, United StatesContact: Boehringer IngelheimNo longer taking part
  • Vantage Clinical Trials - TampaTampa, United StatesContact: Boehringer IngelheimNo longer taking part
  • University of ArizonaTucson, United StatesContact: Boehringer IngelheimNo longer taking part
  • University of Texas Health Science Center at TylerTyler, United StatesContact: Boehringer IngelheimNo longer taking part
  • Cleveland Clinic FloridaWeston, United StatesContact: Boehringer IngelheimNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Boehringer Ingelheim
Trial code
NCT07915219EU 2026-527086-30-00
Record updated
12 November 2026
Original description
This study is for adults and adolescents who are at least 12 years old and have bronchiectasis. People can participate if they completed a previous study with the study medicine called verducatib. The purpose of this study is to find out how well verducatib is tolerated when people with bronchiectasis take it for a long time. The study also looks at breathing problems, how often lung flare-ups happen, and how quickly lung function changes.Read full original descriptionShow less

An Open-label, Roll-over Study Evaluating the Long-term Safety and Efficacy of an Oral Dose of Verducatib q.d. in Patients With Bronchiectasis (AIRTIVITY®-ON)

This study is for adults and adolescents who are at least 12 years old and have bronchiectasis. People can participate if they completed a previous study with the study medicine called verducatib. The purpose of this study is to find out how well verducatib is tolerated when people with bronchiectasis take it for a long time. The study also looks at breathing problems, how often lung flare-ups happen, and how quickly lung function changes.

This is a roll-over study for participants who completed a previous study with verducatib: AIRTIVITY® (1397-0014) or CLAIRLEAF® (1397-0017). All participants receive verducatib. Participants take verducatib as tablets once a day at home. They may continue their usual treatment for bronchiectasis during the study.

Participants can stay in the study for up to 1 year and 9 months. Treatment with verducatib can continue for up to 1 year and 6 months. About 6 study visits are done at the study site and about 4 are done by phone. At all visits, the doctors check participants' health and collect information on any health problems that occur during the study. The doctors also look at lung flare-ups and measure lung function over time.

Inclusion: Participants (adults and adolescents ≥12 years of age) who completed the treatment period in trials 1397-0014 or 1397-0017 as planned per protocol and did not discontinue trial treatment prematurely; Male or female participants. Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per International Council of Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the participant information; Signed and dated written informed consent and assent, if applicable, prior to admission to the trial, in accordance with Good Clinical Practice (GCP) and local legislation.

Exclusion: Participants who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial; Moderate or severe liver disease (defined by Child-Pugh score B or C hepatic impairment), unless the investigator determines it is in the best interest of the participant to enrol in the trial; Any relevant pulmonary, gastrointestinal, hepatic, renal, cardiovascular, metabolic, immunological, hormonal, or other disorder that, in the opinion of the investigator, may put the participant at risk by participating in the study; Participants not expected to comply with the protocol requirements or not expected to complete the trial as scheduled, i.e. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the participant an unreliable trial participant; Further exclusion criteria apply; Estimated glomerular filtration rate (eGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (adults) and Chronic Kidney Disease Under 25 (CKiD-U25) (adolescents) <30 mL/min at Visit 1 (or at the last safety assessment in the parent trial, if no more than 6 weeks passed since then), unless the investigator determines it is in the best interest of the participant to enrol in the trial; An absolute blood neutrophil count <1000/mm\^3 (equivalent to <1000 cells/µL or <10\^9 cells/L) at Visit 1 (or at the last safety assessment in the parent trial, if no more than 6 weeks passed since then); Any findings in the medical examination and/or laboratory value assessed at Visit 1 (or at the last safety assessment in the parent trial, concerning the laboratory tests, if no more than 6 weeks passed since then), that in the opinion of the investigator may put the participant at risk by participating in the trial; Diagnosis of primary or secondary immunodeficiency made after end of treatment in preceding trial.

ClinicalTrials.gov NCT07915219 · EU CTIS 2026-527086-30-00